Keywords
mantle cell lymphoma, cyclin D1, SOX11
How to Cite
Narbaitz, M. (2019). MANTLE CELL LYMPHOMA. The importance of teamwork. Journal of Hematology, 21(3), 296–301. Retrieved from https://revistahematologia.com.ar/index.php/Revista/article/view/168
Abstract
En la observación científica la opinión está íntimamente ligada al conocimiento. Este aporte es consecuencia no sólo del conocimiento que genera el estudio, sino de las horas de trabajo siempre compartidas con otros patólogos y de las diferencias con los demás a la hora de discutir un caso, que sólo dejan enseñanzas positivas.
En los últimos 30 años dentro de la patología, la patología hematológica ha sido la más revolucionada, llevando a la luz los cambios genéticos y moleculares que encontramos en la mayoría de las entidades.
Los aportes son continuos y ellos generan cambios a veces transitorios y otras definitivos; estos cambios la han transformado en una subespecialidad temida e incierta. La única forma de perder el miedo es con el conocimiento y él nos llevará a las certezas del hoy.
References
1. Swerdlow SH, Campo E, Seto M, Muller-Hermelink H. Mantle cell lymphoma. Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic
and Lymphoid Tissues (Revised 4th edition). 2017, 285-290. Lyon.
2. Campo E, Jare P. Mantle cell lymphoma. Jaffe E, Arber DA, Campo E, Harris NL, Quintanilla-Fend L Hematopathology 2nd Edition. 2017, 397-414. Philadelphia.
3. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.
Blood. 2003;101:4975-4981.
4. Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP et al. The splenic form of mantle cell lymphoma. Eur J Haematol. 2002;68:12-21.
5. Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease
progression. Histopathology. 2013;62:334-42.
6. Yin CC, Medeiros LJ, Cromwell CC et al. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell
lymphoma. Mod Pathol. 2007;20:1-7.
7. Mozes A, Roye C, Hartmann E et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555-82.
8. Nakashima MO, Durkin L, Bodo J et al. Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Appl lmmunohistochem Mol Morphol. 2014;22:720-7.
9. Akhter A, Mahe E, Street L et al. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series. J Clin Pathol. 2015;68:844-8.
10. Camacho Fl, Garcia JF, Cigudosa JC et al. Aberrant Bcl6 protein expression in mantle cell lymphoma. Am J Surg Pathol. 2004;28:1051-6.
11. Gao J, Peterson L, Nelson B et al. lmmunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol. 2009;132:699-706.
12. Morice WG, Hodnefield JM, Kurtin PJ et al. An unusual case of leukemic mantle cell lymphoma with a blastoid component showing loss of CD5 and aberrant expression of CD10. Am J Clin Pathol. 2004;122:122-7.
13. Zanetto U, Dong H, Huang Y, Zhang K, Narbaitz M, Sapia S, Bacon CM. Mantle cell lymphoma with aberrant expression of CD10. Histopathology. 2008 Jul;53(1):20-9.
14. Challagundla P, Medeiros LJ, Kanagal-hamanna R et al. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014;142:837-44.
15. Sander B, Quintanilla-Martinez L, Ott G et al. Mantle cell lymphoma-a spectrum from indolent to aggressive disease. Virchows Arch. 2015;468:245- 57.
16. Menter T, Dirnhofer S, Tzankov A. LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol. 2015;68:473-8.
17. Camacho Fl, Algara P, Rodriguez A et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood. 2003;101:4042-6.
18. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features
displays mutated lgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101:4975-81.
19. Rosenwald A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003; 3: 185-197.
20. Scott D et al. for the Lymphoma/Leukemia Molecular Profiling Project. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. JClin Oncol. 2017; 35: 1668-1677.
21. Determann 0, Hoster E, Ott G et al. Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized
trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385-7.
22. Dreyling M, Ferrero S, Vogt N et al. New paradigms in mantle cell lymphoma: is it time to
risk-stratify treatment based on the proliferative signature? Clin Cancer Res. 2014;20:5194- 206.
23. Del Giudice I, Messina M, Chiaretti S et al. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion,
tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. Br J Haematol. 2012;156:601-11.
24. Palomero J, Vegliante MC, Rodriguez ML et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124:2235-47.
25. Carvajal-Cuenca A, Sua LF, Silva NM et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012;97:270-8.
26. Karube K, Scarfo L, Campo E et al. Monoclonal B cell lymphocytosis and “in situ” lymphoma. Semin Cancer Bio. 2014;l. 24:3- 14.
27. Richard P, Vassallo J, Valmary S et al. “In situ-like” mantle cell lymphoma: a report of two cases. J Clin Pathol. 2006;59:995- 6.
28. Nodit L, Bahler DW, Jacobs SA et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003;34:1030-4.
and Lymphoid Tissues (Revised 4th edition). 2017, 285-290. Lyon.
2. Campo E, Jare P. Mantle cell lymphoma. Jaffe E, Arber DA, Campo E, Harris NL, Quintanilla-Fend L Hematopathology 2nd Edition. 2017, 397-414. Philadelphia.
3. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.
Blood. 2003;101:4975-4981.
4. Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP et al. The splenic form of mantle cell lymphoma. Eur J Haematol. 2002;68:12-21.
5. Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease
progression. Histopathology. 2013;62:334-42.
6. Yin CC, Medeiros LJ, Cromwell CC et al. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell
lymphoma. Mod Pathol. 2007;20:1-7.
7. Mozes A, Roye C, Hartmann E et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555-82.
8. Nakashima MO, Durkin L, Bodo J et al. Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Appl lmmunohistochem Mol Morphol. 2014;22:720-7.
9. Akhter A, Mahe E, Street L et al. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series. J Clin Pathol. 2015;68:844-8.
10. Camacho Fl, Garcia JF, Cigudosa JC et al. Aberrant Bcl6 protein expression in mantle cell lymphoma. Am J Surg Pathol. 2004;28:1051-6.
11. Gao J, Peterson L, Nelson B et al. lmmunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol. 2009;132:699-706.
12. Morice WG, Hodnefield JM, Kurtin PJ et al. An unusual case of leukemic mantle cell lymphoma with a blastoid component showing loss of CD5 and aberrant expression of CD10. Am J Clin Pathol. 2004;122:122-7.
13. Zanetto U, Dong H, Huang Y, Zhang K, Narbaitz M, Sapia S, Bacon CM. Mantle cell lymphoma with aberrant expression of CD10. Histopathology. 2008 Jul;53(1):20-9.
14. Challagundla P, Medeiros LJ, Kanagal-hamanna R et al. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014;142:837-44.
15. Sander B, Quintanilla-Martinez L, Ott G et al. Mantle cell lymphoma-a spectrum from indolent to aggressive disease. Virchows Arch. 2015;468:245- 57.
16. Menter T, Dirnhofer S, Tzankov A. LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol. 2015;68:473-8.
17. Camacho Fl, Algara P, Rodriguez A et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood. 2003;101:4042-6.
18. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features
displays mutated lgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101:4975-81.
19. Rosenwald A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003; 3: 185-197.
20. Scott D et al. for the Lymphoma/Leukemia Molecular Profiling Project. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. JClin Oncol. 2017; 35: 1668-1677.
21. Determann 0, Hoster E, Ott G et al. Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized
trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385-7.
22. Dreyling M, Ferrero S, Vogt N et al. New paradigms in mantle cell lymphoma: is it time to
risk-stratify treatment based on the proliferative signature? Clin Cancer Res. 2014;20:5194- 206.
23. Del Giudice I, Messina M, Chiaretti S et al. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion,
tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. Br J Haematol. 2012;156:601-11.
24. Palomero J, Vegliante MC, Rodriguez ML et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124:2235-47.
25. Carvajal-Cuenca A, Sua LF, Silva NM et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012;97:270-8.
26. Karube K, Scarfo L, Campo E et al. Monoclonal B cell lymphocytosis and “in situ” lymphoma. Semin Cancer Bio. 2014;l. 24:3- 14.
27. Richard P, Vassallo J, Valmary S et al. “In situ-like” mantle cell lymphoma: a report of two cases. J Clin Pathol. 2006;59:995- 6.
28. Nodit L, Bahler DW, Jacobs SA et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003;34:1030-4.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar
Downloads
Download data is not yet available.